A Cancer Detection Test Fails in Major Study
AI Summary
A major clinical trial in Britain evaluating Grail's Galleri blood test for early cancer detection failed to demonstrate a reduction in late-stage cancers. The Galleri test, which has been sold in the U.S. since 2021 for $949, screens for cancer DNA in the blood to detect over 50 types of cancer. The study, conducted in partnership with the National Health Service of Britain, involved 142,000 healthy adults aged 50-77 who were followed for three years. Participants had their blood drawn three times, and those who tested positive via Galleri were referred for medical care. The results cast doubt on the effectiveness of blood tests for early cancer detection, despite significant investment and hope in the field.
Key Entities & Roles
Keywords
Sentiment Analysis
Source Transparency
This article was automatically classified using rule-based analysis. The political bias score ranges from -1 (far left) to +1 (far right).
Topic Connections
Explore how the topics in this article connect to other news stories
Find Similar Articles
AI-PoweredDiscover articles with similar content using semantic similarity analysis.